ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lenvatinib

Also written as “Lenvatinib”, “E7080” and “HOPE”.

Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.

Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 19, 201879 company-led studies, 3 open or runningNext primary completion: Oct 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai511 open or runningphase 4since Jun 19, 2018Jul 15, 2005none ahead
Merckits history only261 open or runningphase 3since Jan 22, 2019Aug 3, 2016Oct 22, 2027phase 2 · NCT02861573
AGO Researchits history only11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 1since Oct 4, 2021Oct 4, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eisai only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Jul 15, 2005.

  1. Jun 21, 2016Phase 3 study in Carcinoma, Renal CellNCT02811861 · 1,069 enrolled · United States, Australia, Austria and more
  2. Sep 23, 2016Phase 2 study in Neoplasm MetastasisNCT02915783 · 41 enrolled · United States
  3. Nov 1, 2016Phase 1 study in Unresectable Hepatocellular Carcinoma (HCC)NCT02953743 · 25 enrolled · China
  4. Nov 15, 2016Phase 3 study in Differentiated Thyroid Cancer (DTC)NCT02966093 · 151 enrolled · China
  5. Dec 27, 20163 phase 1 studiesNCT03006926, NCT03006887, NCT03009292
  6. May 22, 2017Phase 2 study in Carcinoma, Renal CellNCT03173560 · 343 enrolled · United States, Australia, Canada and more
  7. Aug 3, 2017Phase 2 study in RecurrenceNCT03245151 · 64 enrolled · United States, Canada
  8. Jan 26, 2018Phase 1 study in Carcinoma, HepatocellularNCT03418922 · 30 enrolled · Japan
  9. Feb 9, 2018Phase 2 study in Carcinoma, HepatocellularNCT03433703 · 8 enrolled · United States
  10. Mar 20, 2018Phase 2 study in Solid TumorsNCT03477175 · 40 enrolled · United States, Australia, Belgium and more
  11. Apr 25, 2018Phase 3 study in Endometrial NeoplasmsNCT03517449 · 827 enrolled · United States, Argentina, Australia and more
  12. Jun 19, 2018Phase 4 study in Thyroid NeoplasmsNCT03573960 · 50 enrolled · India
  13. Nov 1, 2019Phase 2 study in OsteosarcomaNCT04154189 · 81 enrolled · United States, Australia, Austria and more
  14. Mar 4, 2020Phase 4 study in Carcinoma, HepatocellularNCT04297254 · 50 enrolled · India

TargetBeta

“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
AxitinibrulePfizerphase 345
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 51 Eisai leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04297254Carcinoma, Hepatocellular · India4CompletedJul 31, 202350
NCT04154189Osteosarcoma · United States, Australia, Austria and more2CompletedJun 22, 202281
NCT03573960Thyroid Neoplasms · India4CompletedSep 4, 202550
NCT03517449Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedMar 1, 2022827
NCT03477175Solid Tumors · United States, Australia, Belgium and more2CompletedDec 21, 202340
NCT03433703Carcinoma, Hepatocellular · United States2TerminatedJan 7, 20198
NCT03418922Carcinoma, Hepatocellular · Japan1CompletedDec 28, 202230
NCT03245151Recurrence · United States, Canada2CompletedSep 30, 202264
NCT03173560Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedFeb 14, 2020343
NCT03009292Solid Tumor · China1CompletedDec 24, 201812
NCT03006926Carcinoma, Hepatocellular · United States, France, Italy and more1CompletedOct 31, 2019104
NCT03006887Carcinoma, Non-Small-Cell Lung · Japan1CompletedApr 15, 20206
NCT02966093Differentiated Thyroid Cancer (DTC) · China3CompletedJul 31, 2019151
NCT02953743Unresectable Hepatocellular Carcinoma (HCC) · China1CompletedJun 28, 201725
NCT02915783Neoplasm Metastasis · United States2CompletedNov 2, 202141
NCT02811861Carcinoma, Renal Cell · United States, Australia, Austria and more3Active, not recruitingAug 28, 20201,069
NCT02702388Thyroid Neoplasms · United States, Australia, Belgium and more2CompletedDec 12, 2019241
NCT02686164Neoplasms · United States1CompletedJan 4, 201751
NCT02657369Thyroid Carcinoma, Anaplastic · United States, Australia, France and more2TerminatedSep 26, 201834
NCT02579616Biliary Tract Neoplasms · Japan2CompletedNov 22, 201629
NCT02792829Healthy Volunteers · United States1CompletedAug 201460
NCT02723630Healthy Volunteers · United States1CompletedAug 201360
NCT02578316Lymphoma · Netherlands1CompletedJun 20106
NCT02501096Neoplasms · United States, Norway, Spain2CompletedAug 18, 2020357
NCT02454478Carcinoma, Renal Cell · Japan1CompletedMay 29, 20177
NCT02432274Neoplasms · United States, France, Germany and more2CompletedJul 18, 2019117
NCT02421042Hepatic Impairment · United States1CompletedJul 201214
NCT02199392P-glycoprotein · United States1CompletedJan 201215
NCT02199379Renal Insufficiency · United States1CompletedOct 201226
NCT02198170Healthy Volunteers · United States1CompletedJun 201118
NCT01877083Lung Neoplasms · United States, Hong Kong, Japan and more2CompletedFeb 3, 201625
NCT01761266Carcinoma, Hepatocellular · United States, Australia, Belgium and more3CompletedNov 13, 2016954
NCT01728623Thyroid Neoplasms · Japan2CompletedJul 9, 201551
NCT01525394Lymphoma · United States1CompletedAug 201152
NCT01529112Carcinoma, Non-Small-Cell Lung · United States, Belgium, Czechia and more2CompletedJan 21, 2014135
NCT01433991Advanced Solid Tumors · United States2TerminatedMar 18, 201530
NCT01321554Thyroid Neoplasms · United States, Argentina, Australia and more3CompletedNov 15, 2013392
NCT01268293Neoplasms · Japan1CompletedDec 20119
NCT01240408Neoplasms · United States1CompletedNov 201116
NCT01137604Glioma · United States, Canada2CompletedMar 19, 2013151
NCT01136967Melanoma · United States, Australia, Germany and more2CompletedApr 2013182
NCT01136733Carcinoma, Renal Cell · United States, Czechia, Poland and more2CompletedJun 13, 2014173
NCT01133977Melanoma · United States, Germany, Italy and more2CompletedJun 201497
NCT01133756Ovarian Neoplasms · United States2TerminatedFeb 20127
NCT01111461Endometrial Neoplasms · United States, Belgium, Bulgaria and more2CompletedMay 2012133
NCT00946153Carcinoma, Hepatocellular · Japan, Korea, Republic of2CompletedJun 15, 201466
NCT00832819Carcinoma, Non-Small-Cell Lung · Japan1CompletedJul 201128
NCT00784303Thyroid Neoplasms · United States, Australia, France and more2CompletedApr 11, 2011117
NCT00280397Neoplasms · Japan1CompletedSep 200827
NCT00121719Lymphoma · Netherlands, United Kingdom1CompletedJun 19, 200982
NCT00121680Melanoma · United States1CompletedSep 2011115

How it is read

Names in the registry

  • “Lenvatinib”, 72 entries
  • “lenvatinib”, 7 entries
  • “E7080”, 6 entries
  • “HOPE”, 2 entries
  • “E7080 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.